These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
157 related items for PubMed ID: 11130332
1. Comparison of 99Tcm-tetrofosmin with 201Tl and 131I in the detection of differentiated thyroid cancer metastases. Nishiyama Y, Yamamoto Y, Ono Y, Takahashi K, Nakano S, Satoh K, Ohkawa M, Tanabe M. Nucl Med Commun; 2000 Oct; 21(10):917-23. PubMed ID: 11130332 [Abstract] [Full Text] [Related]
2. Thallium-201, technetium-99m-tetrofosmin and iodine-131 in detecting differentiated thyroid carcinoma metastases. Unal S, Menda Y, Adalet I, Boztepe H, Ozbey N, Alagöl F, Cantez S. J Nucl Med; 1998 Nov; 39(11):1897-902. PubMed ID: 9829579 [Abstract] [Full Text] [Related]
3. Value of combined technetium-99m hydroxy methylene diphosphonate and thallium-201 imaging in detecting bone metastases from thyroid carcinoma. Alam MS, Takeuchi R, Kasagi K, Misaki T, Miyamoto S, Iida Y, Hidaka A, Konishi J. Thyroid; 1997 Oct; 7(5):705-12. PubMed ID: 9349573 [Abstract] [Full Text] [Related]
4. Thyroglobulin and low-dose iodine-131 and technetium-99m-tetrofosmin whole-body scintigraphy in differentiated thyroid carcinoma. Gallowitsch HJ, Mikosch P, Kresnik E, Unterweger O, Gomez I, Lind P. J Nucl Med; 1998 May; 39(5):870-5. PubMed ID: 9591591 [Abstract] [Full Text] [Related]
5. Determination of medullary thyroid carcinoma metastases by 201Tl, 99Tcm(V)DMSA, 99Tcm-MIBI and 99Tcm-tetrofosmin. Adalet I, Koçak M, Ogŭz H, Alagöl F, Cantez S. Nucl Med Commun; 1999 Apr; 20(4):353-9. PubMed ID: 10319355 [Abstract] [Full Text] [Related]
6. Technetium-99m-tetrofosmin whole-body scintigraphy in the follow-up of differentiated thyroid carcinoma. Lind P, Gallowitsch HJ, Langsteger W, Kresnik E, Mikosch P, Gomez I. J Nucl Med; 1997 Mar; 38(3):348-52. PubMed ID: 9074515 [Abstract] [Full Text] [Related]
7. Comparison of 201Tl, 99Tcm-MIBI and 131I imaging in the follow-up of patients with well-differentiated thyroid carcinoma. Uğur O, Kostakoğlu L, Caner B, Güler N, Gülaldi NC, Ozmen M, Uysal U, Elahi N, Erbengi G, Bejdik C. Nucl Med Commun; 1996 May; 17(5):373-7. PubMed ID: 8736512 [Abstract] [Full Text] [Related]
8. Relationship between expression of the sodium/iodide symporter and 131I uptake in recurrent lesions of differentiated thyroid carcinoma. Min JJ, Chung JK, Lee YJ, Jeong JM, Lee DS, Jang JJ, Lee MC, Cho BY. Eur J Nucl Med; 2001 May; 28(5):639-45. PubMed ID: 11383871 [Abstract] [Full Text] [Related]
13. Relative value of thallium-201 and iodine-131 scans in the detection of recurrence or distant metastasis of well differentiated thyroid carcinoma. Lin JD, Kao PF, Weng HF, Lu WT, Huang MJ. Eur J Nucl Med; 1998 Jul; 25(7):695-700. PubMed ID: 9662590 [Abstract] [Full Text] [Related]
19. The use of non-specific tracers in the follow up of differentiated thyroid cancer: results with Tc-99m tetrofosmin whole body scintigraphy. Lind P, Gallowitsch HJ. Acta Med Austriaca; 1996 Jul; 23(1-2):69-75. PubMed ID: 8767519 [Abstract] [Full Text] [Related]
20. Comparison of 99mTc-methoxyisobutyl isonitrile and 201Tl scintigraphy for detection of residual thyroid cancer after 131I ablative therapy. Seabold JE, Gurll N, Schurrer ME, Aktay R, Kirchner PT. J Nucl Med; 1999 Sep; 40(9):1434-40. PubMed ID: 10492361 [Abstract] [Full Text] [Related] Page: [Next] [New Search]